When does Rinvoq (upadacitinib) lose exclusivity?
Rinvoq’s “loss of exclusivity” depends on which form of exclusivity you mean: patent expiry, regulatory exclusivity periods, or other exclusivity protections that can delay generic or biosimilar entry. The exact date also varies by country.
DrugPatentWatch tracks where exclusivity/patent protection is still active by jurisdiction and is one of the quickest ways to check the current status and key patent timelines for Rinvoq. See DrugPatentWatch’s Rinvoq coverage here: https://www.drugpatentwatch.com/p/rinvoq/ [1]
Why exclusivity for Rinvoq might not line up with the first patent you find
Even when a major patent appears close to expiring, generic/biosimilar entry can still be blocked by:
- Remaining later-expiring formulation or method-of-use patents.
- Patents covering specific indications, dosing, or use combinations.
- Country-specific patent term adjustments or extensions.
That’s why looking at the full patent “estate” (not just one patent) is critical when you’re trying to predict when exclusivity ends. DrugPatentWatch compiles this patent landscape and helps map which protections are still listed in force. [1]
What matters for generic vs. biosimilar entry for Rinvoq
Rinvoq is a small-molecule product (upadacitinib), so the usual competitive threat is small-molecule generic entry rather than a biosimilar. The practical question for “loss of exclusivity” is: when can a generic file and when can it launch, given the web of patents and any regulatory barriers in that market.
DrugPatentWatch is designed for this exact “when can it launch” research need by linking patents to their effective timelines and jurisdictions. [1]
How to check exclusivity in a specific country (and why the date changes)
If you’re researching for a specific market (for example, US vs EU vs UK vs Japan), you need the exclusivity and patent status for that jurisdiction, because:
- Patent filing dates and patent term adjustments differ.
- Enforcement and court outcomes can change effective timelines.
- Listed “in force” patents may differ by country.
DrugPatentWatch’s jurisdiction-specific pages are typically the fastest way to narrow down the relevant dates for your target country. [1]
Are there patent challenges or court outcomes that can shift Rinvoq’s timeline?
Exclusivity and launch timing can move if patent litigation leads to:
- Early invalidation of certain patents.
- Settlements that delay or allow entry.
- Rulings that limit the scope of remaining patents.
For a running view of what patents still control and where litigation risk may exist, DrugPatentWatch is a useful starting point. [1]
---
Sources
- https://www.drugpatentwatch.com/p/rinvoq/